logo
The Baseline
29 Sep 2026
Five stocks to buy from analysts this week - September 29, 2026
By Abdullah Shah

1. Century Plyboards (India):

Axis Direct initiates coverage on this wood-panel manufacturer with a ‘Buy’ rating and a target price of Rs 820, an upside of 23.3%. Analysts Eesha Shah and Vishal Jagwani expect Century Plyboards’ next expansion phase to drive its revenue target of Rs 12,000 crore by FY30-31. 

The company is building a new plywood plant in Punjab, investing Rs 1,130 crore in a medium-density fibreboard (MDF) and plywood project in Uttar Pradesh, and phasing development of an Odisha facility. Plywood currently contributes around 54% of its revenue, but the company is reducing its reliance on the segment by expanding newer businesses like MDF. Management anticipates MDF to match its plywood business size within two to three years. They target a 15%+ EBITDA margin for the segment, while analysts project MDF revenue to grow 20% annually over FY27-29.

Shah and Jagwani predict that new plants and higher factory usage will boost profitability from FY27. Analysts forecast overall revenue, EBITDA, and net profit CAGRs of 17%, 24%, and 35% through FY27-29. The company also aims to increase its plywood market share from around 10% to 15% over the medium term, supported by 12-15% annual volume growth over five years. 

2. Thangamayil Jewellery:

BOB Capital Markets upgrades this jewellery retailer to a ‘Buy’ rating from ‘Hold’, with a target price of Rs 6,314, an upside of 21.3%. Analysts Lavita Lasrado and Nistha Pala believe that store expansion will drive the next phase of growth, with Chennai at the centre of the plan. 

Thangamayil aims to increase its Greater Chennai network from 14 to 25 stores over the next 18 months. Chennai already generates 20-23% of total revenue. The company also plans to open roughly 10 stores every year across Tamil Nadu over the next three to four years before entering other states.

Management projects this expansion will drive a 25% revenue increase while maintaining an EBITDA margin near 6%. Jewellery demand dropped in Q1FY27 as high gold prices deterred buyers. However, recent gold price drops have revived customer interest. Management notes that buyers delayed rather than cancelled purchases, and expects festive and wedding demand to power a recovery in H2FY27.

Lasrado and Pala highlight strong store productivity, with inventory turnover of 3.2 times annually, beating management’s target of 2.5-3 times. They forecast earnings per share to grow at a 24% CAGR over FY27-29, backed by new stores, demand recovery, and steady sales at existing locations.

3. Pearl Global Industries (PGIL): 

ICICI Direct upgrades this apparel maker to a ‘Buy’ rating from ‘Hold ’, with a higher target price of Rs 1,600, an upside of 24%. Analysts Kaustubh Pawaskar and Abhishek Shankar believe PGIL’s manufacturing presence across several countries gives it an advantage in serving global customers and increasing its share of exports.

The company plans to increase its annual apparel production capacity from 10.1 crore pieces in FY26 to 17-17.5 crore pieces. Its factories in Bangladesh, Vietnam, Indonesia and Guatemala are already operating at 80-90% capacity, leaving limited room to handle additional orders without expansion. 

PGIL also plans to add capacity in India, supported by government incentives for textile manufacturing and new free trade agreements (FTAs). The UK is estimated to become a bigger market, with analysts forecasting its contribution to revenue to rise from around 4% currently to 10% by FY30, helped by the India-UK FTA.

Pawaskar and Shankar believe PGIL’s diverse production and broad customer base also reduce its dependence on any single market. This has helped the company manage disruptions such as the West Asia conflict and US tariffs. Management targets revenue of Rs 9,000-10,000 crore by FY30, implying 16-18% annual growth, driven by new customers, higher business from existing clients, expansion into new product categories and better utilisation of its factories.

4. SPR Auto Technologies: 

Motilal Oswal initiates coverage on this auto parts maker with a ‘Buy’ rating and a target price of Rs 6,150, an upside of 29.5%. Analysts Radha Agarwalla and Jeemit Shah note that SPR is transforming from a traditional piston maker into a diversified mobility platform via acquisitions. This strategy builds a scalable auto component platform with balanced exposure across powertrains.

SPR remains a strong player in its core piston business, with around 45% market share. Analysts expect this business to continue growing as pistons are still required in petrol, diesel and other fuel-based engines. The company is also increasing sales in the replacement market and industries outside automobiles, reducing its dependence on any one segment. At the same time, the exit of some global competitors from conventional engine components could help SPR gain incremental market share.

Agarwalla and Shah report that recent acquisitions of Antolin, Takahata, Timex Group Precision Engineering, and EMF Innovations generate about 35% of revenue. These businesses have expanded the company into precision plastic components while giving it a wider mix of products, customers and markets. They project a revenue and net profit CAGR of about 21% over FY27-29. 

5. Dr Lal PathLabs (DLPL): 

Emkay retains its ‘Buy’ rating on this healthcare diagnostics provider and raises its target price to Rs 2,100, an upside of 7.7%. Analysts Anshul Agrawal and Vivek Sethia forecast DLPL to benefit from its strong market position as more customers move towards organised diagnostic chains and preventive health testing becomes more common.

The company has approved the acquisition of a 70% stake in SN Genelab, a diagnostics company focused on serving hospitals, laboratories and other businesses, for Rs 168 crore. Management projects the deal to strengthen DLPL’s range of specialised tests and reduce its dependence on any one region. Analysts anticipate DLPL to cross-sell SN Genelab tests across its B2B and B2C channels, with revenue gains reflecting in the next two to three years.

Agrawal and Sethia also see advanced testing as an important growth area for the company. DLPL is investing in genomics, which uses genetic information to help diagnose and understand diseases. These capabilities could help it offer more specialised services and stand out from other large diagnostic chains. The analysts expect revenue to grow at a 14.6% CAGR and net profit at a 16.7% CAGR through FY29.

 

Note: These recommendations are from various analysts and are not recommendations by Trendlyne.

(You can find all analyst picks here)

More from The Baseline
More from Abdullah Shah
Recommended